On Wednesday, November 1, 2017, the Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management (DSRM) Advisory Committee supported approval of some of the proposed doses of buprenorphine subcutaneous injection (CAM2038), submitted by Braeburn Pharmaceuticals, Inc., (Braeburn), for the treatment of opioid dependence.
Back to All Events
Earlier Event: November 1
Clinical Laboratory Improvement Advisory Committee
Later Event: November 7
Vaccines and Related Biological Products Advisory Committee